BLACK WEEKSInjektiopullot −15 % · kitit −10 % · muut −5 %koodillaIlmainen toimitus Saksaan alk. €200

Tämä sivu on käännetty automaattisesti, ja siinä voi olla virheitä. Onko suomi äidinkielesi? Otamme mielellämme vastaan palautetta ja korjauksia.Lähetä palautetta

The Peptide Desk The Peptide Desk
Semaglutide Oral, tuotekuva
GLP-1 Oral

Semaglutide Oral

GLP-1 Oral

  • Lähetetään Saksasta

Tilaus

Kappalehinta - Ilmainen toimitus Saksaan yli 200 €:n tilauksille Black Weeksin aikana
  • DHL seurannalla
  • Huomaamaton pakkaus

4.6/5 Trustpilotissa73 arvostelua

Haettu myös nimellä: Semaglutid Oral · Semaglutid Tabletten

Yhdellä silmäyksellä

Semaglutide Oral lukuina

Tietopankkimme keskeiset luvut.

Koko tietopankkiartikkeli
Class
GLP-1 agonistoral
Half-life
longdosed daily
Use
Oral, fastedin mg/day
Sizes
2 sizes3mg/25tabs, 7mg/25tabs

Tuotteelle Semaglutide Oral ei ole vielä laboratorioanalyysia. Äänestä sitäTestauta itse, me maksamme puoletKaikki laboratorioanalyysit

Tietoa

Kaikki aiheesta Semaglutide Oral

FAQ

Usein kysyttyä

Lähteet jokaiseen vastaukseen: tietopankkiartikkeli

Onko sinulla vielä kysyttävää?

Kirjoita meille, tiimimme auttaa sinua.

Is this the same compound as the injection?

Yes. Semaglutide is a GLP-1 analogue with 94 percent sequence match to the body's own GLP-1. The tablet also contains SNAC, which enables absorption in the stomach. Because only a small part arrives, the milligram figures are higher than with the injection.

Is oral semaglutide approved?

Yes. ChEMBL lists semaglutide as an approved compound with first approval in 2017, the tablet has its own US label. On ClinicalTrials.gov a search for oral semaglutide gives 204 trials (as of 26 October 2026). Everything here is the state of research, not a recommendation.

Why fasted and with little water?

According to the label only about 0.4 to 1 percent reaches the blood. In studies in healthy people absorption was higher with little water than with a large glass. The longer nothing was eaten after the tablet, the more arrived. Hence the strict intake rule in the entry.

What did PIONEER 1 show?

703 people with type 2 diabetes using only diet and exercise received one of three doses or placebo. After 26 weeks HbA1c was 0.6 to 1.1 percentage points lower than with placebo. Weight fell clearly only on the highest study dose, by 2.3 kg more than on placebo.

What about the heart?

PIONEER 6 with 3,183 people showed that cardiovascular risk does not rise (3.8 versus 4.8 percent). SOUL with 9,650 people with vascular or kidney disease found 12.0 instead of 13.8 percent major events over about four years, so 14 percent fewer.

Which side effects are typical?

Mainly gastrointestinal complaints. According to the label 20 percent had nausea on the highest study dose, 6 percent on placebo. In addition there were abdominal pain, diarrhoea, decreased appetite, vomiting and constipation. The label also names rare risks such as pancreatitis and gallbladder problems.

Liittyvät

Samankaltaiset tuotteet